每经头条（nbdtoutiao）——一次自救，"奥特曼"竟埋下百亿元损失的"时间炸弹"，现在被引爆！有人 却在疯狂赚钱⋯⋯ （记者 张明双） 截至发稿，*ST赛隆市值为24亿元。 每经AI快讯，*ST赛隆（SZ 002898，收盘价：13.75元）9月12日晚间发布公告称，公司第四届第十四次 董事会会议于2025年9月12日在珠海市香洲区南湾北路31号2单元21层公司会议室以现场及通讯相结合的 方式召开。会议审议了《关于续聘公司2025年度审计机构的议案》等文件。 2025年1至6月份，*ST赛隆的营业收入构成为：医药制造业占比59.82%，电子行业占比39.78%，其他业 务占比0.4%。 ...

截至发稿，贵州三力市值为53亿元。 每经AI快讯，贵州三力（SH 603439，收盘价：12.89元）9月12日晚间发布公告称，截至2025年9月12 日，回购期限已届满，公司完成回购。公司通过集中竞价交易方式已实际回购公司股份7,869,300股，已 回购股份占公司总股本的比例为1.92%，最高成交价格为人民币14.20元/股，最低成交价格为人民币 11.82元/股，回购平均价格为12.70元/股，已支付的资金总额为人民币99,954,426.00元（不含交易费 用），本次回购股份符合相关法律法规的有关规定和公司回购方案的要求。 2024年1至12月份，贵州三力的营业收入构成为：医药制造业占比99.97%，其他业务占比0.03%。 （记者 王晓波） 每经头条（nbdtoutiao）——一次自救，"奥特曼"竟埋下百亿元损失的"时间炸弹"，现在被引爆！有人 却在疯狂赚钱⋯⋯ ...

人民财讯9月12日电，9月11日，工业和信息化部党组书记、部长李乐成主持召开医药行业制造业企业座 谈会。李乐成强调，要加快实施医药工业高质量发展行动，夯实企业创新主体地位，推进人工智能向医 药全产业链深度赋能，加大知识产权保护力度，依法依规引导企业有序竞争，不断优化市场环境和发展 生态。 ...

交易信息汇总资金流向 9月10日主力资金净流出470.2万元；游资资金净流出216.91万元；散户资金净流入687.11万元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 董秘： 投资者，您好！感谢您对公司的关注，不同机构在行业分类时侧重点不同导致分类出现差异， 公司在证监会行业信息里划分为医药制造业，谢谢。 投资者： 为什么同样是三甲医院，金陵药业旗下的宿迁医院，近年来营收停滞，利润持续减少，而国 际医学旗下的西安高新医院，营收和利润持续增长呢？请管理层给广大股东解释一下！ 董秘： 投资者，您好！感谢您对公司的关注，相关信息请参考公司在指定媒体披露的公告，谢谢！ 当日关注点 来自交易信息汇总：9月10日主力资金净流出470.2万元，散户资金净流入687.11万元。 截至2025年9月10日收盘，金陵药业(000919)报收于7.2元，下跌0.28%，换手率1.15%，成交量6.79万 手，成交额4891.16万元。 董秘最新回复 投资者： 金陵药业现在医疗服务板块的营收占比超过50%，但是同花顺是显示公司还属于化学制药行 业， ...

证券代码：002565 证券简称：顺灏股份 上海顺灏新材料科技股份有限公司投资者关系活动记录表 编号：2025-004 | 投资者关系活动类别 ☑ | 特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | □其他 | | | 参与单位名称与姓名 | 国诚投资胡均师、王秋楠 | | 时间 2025 | 年 9 月 10 日（星期三）14:00-15:30 | | 地点 | 公司会议室 | | 上市公司接待人员姓 | 董事会秘书兼副总裁：杜云波先生 | | 名 | 证券事务专员：尚云云女士 | | | 一、杜云波先生介绍公司整体业务情况 | | | 二、问答环节： | | | Q1：公司坚持 "环保低碳新材料 + 生物大健康" 双翼发展战略， | | | 在当前市场环境下，如何进一步平衡和协同这两大业务板块，以实 | | | 现可持续增长？ | | | 答：公司始终坚持"环保低碳新材料+生物大健康"双翼发展的战 | | 投资者关系活动主要 | 略布局，围绕特种环保纸的研发、生产及销售，印刷品的研发、生 | ...

Core Viewpoint - Chengda Pharmaceutical (301201.SZ) is experiencing poor performance, leading to continuous share reductions by original shareholders, particularly Shenzhen Qianhai Shengtai Investment Enterprise, which plans to sell up to 11 million shares, potentially cashing out 316 million yuan [1][3][9]. Group 1: Shareholder Actions - Shenzhen Qianhai Shengtai plans to reduce its holdings by up to 11 million shares, representing 7.27% of the company's total shares, within three months starting from September 29, 2025 [2][3]. - Over the past two and a half years, Qianhai Shengtai has reduced its holdings in Chengda Pharmaceutical, cashing out a total of 634 million yuan [1][9]. - The latest reduction plan follows a series of previous reductions, with Qianhai Shengtai having already cashed out 318 million yuan from earlier sales [8][9]. Group 2: Company Performance - For the first half of 2025, Chengda Pharmaceutical reported revenue of 182 million yuan, an increase of 11.24% year-on-year, but net profit fell by 49.06% to 12.82 million yuan [11][12]. - The company's stock price has dropped over 60% from its initial public offering price of 72.69 yuan, with the current price at 28.74 yuan [9][10]. - Chengda Pharmaceutical's revenue and net profit have shown a declining trend over the past few years, with a notable loss of 28.1 million yuan in 2024, marking the first loss since 2010 [12][13]. Group 3: Business Challenges - The decline in revenue is attributed to a 33.22% drop in sales of raw materials, particularly due to clients overstocking in anticipation of national centralized procurement [12][13]. - The CDMO (Contract Development and Manufacturing Organization) segment also faced a 37.65% decline in sales due to increased competition and global economic uncertainties [12][13]. - Chengda Pharmaceutical aims to expand its market presence and enhance its brand value through various promotional activities and by deepening relationships with existing clients [13].

Group 1 - Gannee Pharmaceutical has completed a share buyback, acquiring a total of 3.540021 million shares, which represents 0.589% of the company's total share capital [1] - The highest transaction price during the buyback was 45.14 CNY per share, while the lowest was 37.65 CNY per share, with an average buyback price of 42.39 CNY per share [1] - The total amount spent on the buyback was approximately 150 million CNY [1] Group 2 - For the year 2024, Gannee Pharmaceutical's revenue composition is entirely from the pharmaceutical manufacturing industry, accounting for 100.0% [1] - The current market capitalization of Gannee Pharmaceutical is 45 billion CNY [2]

Group 1 - The A-share market opened with mixed performance among major indices, with the Shanghai Composite Index down by 0.11% at 3761.88 points, while the Shenzhen Component Index rose by 0.18% to 12140.76 points, and the ChiNext Index increased by 0.49% to 2789.91 points [2][3] - The sports industry, AI mobile phones, and CPO concepts showed significant gains, while precious metals, wind power equipment, and cultivated diamonds experienced declines [2][3] - The sports industry sector specifically rose by 2.09%, indicating strong investor interest in this area [3] Group 2 - The Hong Kong stock market opened positively, with the Hang Seng Index up by 0.31% and the Hang Seng Tech Index increasing by 0.42%, reflecting a recovery in the pharmaceutical sector [4] - The People's Bank of China conducted a 7-day reverse repurchase operation amounting to 188.3 billion yuan, maintaining the operation rate at 1.40% [5] - The Chinese yuan depreciated against the US dollar by 12 basis points, with the central parity rate reported at 7.1064 [6]

Group 1 - The core point of the news is that Hualan Co., Ltd. experienced a 5.25% drop in stock price, closing at 33.38 yuan per share, with a trading volume of 208 million yuan and a turnover rate of 3.84%, resulting in a total market capitalization of 5.481 billion yuan [1] - Hualan Co., Ltd. is based in Jiangyin City, Jiangsu Province, and was established on June 4, 1992, with its listing date on November 1, 2021. The company specializes in the research, production, and sales of packaging materials for injectable drugs [1] - The main business revenue composition of Hualan Co., Ltd. includes 49.07% from film-coated rubber stoppers, 48.50% from conventional rubber stoppers, and 2.43% from other products [1] Group 2 - From the perspective of major fund holdings, one fund under Galaxy Fund has a significant position in Hualan Co., Ltd. The Galaxy Kangle Stock A fund (519673) reduced its holdings by 22,800 shares in the second quarter, now holding 355,900 shares, which accounts for 6.37% of the fund's net value, making it the largest holding [2] - The Galaxy Kangle Stock A fund was established on November 18, 2014, with a latest scale of 155 million yuan. Year-to-date returns are 30.98%, ranking 1067 out of 4222 in its category; the one-year return is 56.28%, ranking 1381 out of 3789; and since inception, the return is 172.7% [2] - The fund manager of Galaxy Kangle Stock A is Fang Wei, who has been in the position for 4 years and 119 days, with the total asset scale of 671 million yuan. The best fund return during his tenure is -3.58%, while the worst is -17.61% [2]

Core Insights - Hongyuan Pharmaceutical experienced a decline of 1.51% on September 3, with a trading volume of 45.42 million yuan [1] - The company reported a net financing outflow of 3.80 million yuan on the same day, with a total financing and securities balance of 107 million yuan [1] - As of June 30, the company recorded a revenue of 883 million yuan for the first half of 2025, a year-on-year decrease of 1.73%, and a net profit attributable to shareholders of -5.81 million yuan, down 116.23% year-on-year [2] Financing and Trading Activity - On September 3, Hongyuan Pharmaceutical had a financing buy-in of 3.24 million yuan, with a current financing balance of 107 million yuan, representing 3.59% of its market capitalization [1] - The company's financing balance is above the 80th percentile of the past year, indicating a high level of financing activity [1] - The short-selling activity on the same day included 100 shares sold, with a total value of 1,431 yuan, and a short-selling balance of 21,180 yuan, which is below the 30th percentile of the past year [1] Shareholder and Dividend Information - As of June 30, the number of shareholders increased by 3.27% to 31,000, while the average number of circulating shares per person decreased by 4.20% to 5,155 shares [2] - Since its A-share listing, Hongyuan Pharmaceutical has distributed a total of 71.81 million yuan in dividends [3] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is a new entrant, holding 1.30 million shares, while Southern CSI 1000 ETF has exited the list [3]